Haisco Pharma invested $10 million in North Carolina’s Pneuma Respiratory in return for China rights to Pneumahaler™, a breath-activated digital inhaler intended for asthma and COPD. Initially, Pneuma intends to use the device to deliver off-patent medications, but the company believes the Pneumahaler will eventually prove to be an effective delivery tool for biologic medications. According to Pneuma, the device combines advanced droplet ejector technology with digitally controlled breath-actuation.
Source: China Biotoday
